Page last updated: 2024-12-04

2-amino-5-phosphonovalerate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1216
CHEMBL ID28862
CHEBI ID138644
SCHEMBL ID158652
MeSH IDM0024150

Synonyms (90)

Synonym
EU-0100018
dl-2-amino-5-phosphonopentanoic acid, solid
2-amino-5-phosphonovalerate
c5h12no5p
5-phosphononorvaline
dl-apv
2-amino-5-phosphonovaleric acid
2-apv
norvaline, 5-phosphono-
app acid
LOPAC0_000018
2-amino-5-phosphopentanoic acid
76326-31-3
NCGC00024470-02
NCGC00024470-03
2-amino-5-phosphonopentanoic acid ,
(?)-2-amino-5-phosphonopentanoic acid
dl-2-amino-5-phosphonopentanoic acid
MLS002153456
smr000326892
NCGC00015065-03
2-amino-5-phosphovaleric acid
CHEBI:138644 ,
( inverted question mark)-ap-5; ( inverted question mark)-ap-v
A 5282
( inverted question mark)-2-amino-5-phosphonopentanoic acid
NCGC00015065-05
inchi=1/c5h12no5p/c6-4(5(7)8)2-1-3-12(9,10)11/h4h,1-3,6h2,(h,7,8)(h2,9,10,11)
voroeqbfppiacj-uhfffaoysa-
CHEMBL28862 ,
AKOS005067826
(r)-2-amino-5-phosphono-pentanoic acid
2-amino-5-phosphono-pentanoic acid(r-ap5)
2-amino-5-phosphono-pentanoic acid(d-ap5)
dl-2-amino-5-phosphonovaleric acid
2-amino-5-phosphono-pentanoic acid
2-amino-5-phosphono-pentanoic acid anion
2-amino-5-phosphono-pentanoic acid(s-ap5)
dl-2-amino-5-phosphono valericacid
(r)-2-amino-5-phosphonopentanoicacid
(apv)2-amino-5-phosphono-pentanoic acid
bdbm50004897
HMS3260C17
CCG-204114
NCGC00015065-04
FT-0641590
dl-norvaline, 5-phosphono-
unii-39pj29yy8z
39pj29yy8z ,
apv acid
LP00018
(+/-)-2-amino-5-phosphonopentanoic acid
5-phosphono-dl-norvaline
ap 5 (+/-)-
norvaline, 5-phosphono- (+/-)-
(+/-)-amino-5-phosphonopentanoic acid
apv (+/-)-
ap-5 (+/-)-
dl-ap-5
ap 5 (amino acid)
(+/-)-2-amino-5-phosphonovaleric acid
76726-92-6
SCHEMBL158652
(y)-2-amino-5-phosphonopentanoic acid
NCGC00260703-01
tox21_500018
dl-ap5
HB0251
(+/-)-amino-5-phosphono-pentanoic acid
mfcd00010515
dl-2-amino-5-phosphonovaleric acid, 98%
sr-01000075417
SR-01000075417-1
SR-01000075417-3
FT-0771646
DTXSID90893701
BD162539
Q27105144
l-2-amino-5-phosphonopentanoic acid; l-2-amino-5-phosphonovaleric acid
5-phosphononorvaline; (+/-)-2-amino-5-phosphonovaleric acid; 2-apv; ap 5; apv
EX-A7666
SDCCGSBI-0050007.P002
NCGC00015065-09
STL565728
2-amino-5-phosphonopentanoic acid.
AKOS037623587
dl-2-amino-5-phosphonovaleric acid (ap5)
5-phosphononorvaline; ()-2-amino-5-phosphonovaleric acid; 2-apv; ap 5; apv
HY-100714
CS-0020138

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The neurotoxicity induced by carbamazepine may be involved in the teratogenic and adverse effects of overdose associated with the treatment of manic-depressive illness and seizures."( Carbamazepine-induced neurotoxicity and its prevention by NMDA in cultured cerebellar granule cells.
Chuang, DM; Gao, XM, 1992
)
0.28
") were also resistant to the toxic effects of quisqualic acid, indicating the possible involvement of NMDA receptors in quisqualic acid toxicity."( Quisqualic acid-induced neurotoxicity is protected by NMDA and non-NMDA receptor antagonists.
Pai, KS; Ravindranath, V, 1992
)
0.28
" The antagonistic properties of kynurenate were dose-dependent: equimolar kynurenate had no effect on quinolinate but attenuated the actions of ibotenate, kainate and NMDA; 2 x equimolar kynurenate had no effect on quinolinate or ibotenate but attenuated the toxicity of kainate and NMDA; and 3 x equimolar kynurenate had no effect on the toxicity of kainate or ibotenate, attenuated the actions of NMDA and abolished the toxic action of quinolinate."( A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.
Clark, AJ; Hastings, MH; Latimer, M; Stone, TW; Winn, P, 1991
)
0.28
" No toxic effect of quisqualate is observed."( Kainate and NMDA toxicity for cultured developing and adult rat spiral ganglion neurons: further evidence for a glutamatergic excitatory neurotransmission at the inner hair cell synapse.
Delrée, P; Lefebvre, PP; Leprince, P; Moonen, G; Rigo, JM; Rogister, B; Weber, T, 1991
)
0.28
" Reducing the glutamate level of macrophage SN, either by exposure to astrocytes or by enzymatic degradation abolished the toxic effect."( Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate.
Cuénod, M; Do, KQ; Fontana, A; Frei, K; Piani, D, 1991
)
0.28
" The effects of EAA co-incubation with the N-methyl-D-aspartate (NMDA) receptor antagonist, 2-amino-5-phosphonovaleric acid, suggested that the toxic actions of quinolinate, but not kainate, were mediated largely by NMDA receptors."( Quinolinate and kainate neurotoxicity in neostriatal cultures is potentiated by co-culturing with neocortical neurons.
Galarraga, E; Kitai, ST; Surmeier, DJ, 1990
)
0.28
" Morphological criteria were used to determine the toxic effects of glutamate in 6-, 12-, and 18-day-old cultures which were examined before and after 1-3 h of exposure to glutamate."( Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures.
Beal, MF; DiFiglia, M; Freese, A; Koroshetz, WJ; Martin, JB, 1990
)
0.28
" At a concentration that was not toxic by itself, L-trans-pyrrolidine-2,4-dicarboxylate increased the toxicity of glutamate approximately fivefold and slowed the clearance of glutamate from the extracellular space."( Inhibition of glutamate uptake with L-trans-pyrrolidine-2,4-dicarboxylate potentiates glutamate toxicity in primary hippocampal cultures.
Buchhalter, JR; Djali, S; Robinson, MB, 1993
)
0.29
" Dopamine caused a dose-dependent loss of neurons and reduction of neurites immunoreactive to tyrosine hydroxylase with a LD50 of about 100 microM."( Neurotoxicity of dopamine and protective effects of the NMDA receptor antagonist AP-5 differ between male and female dopaminergic neurons.
Andrae, J; Lieb, K; Pilgrim, C; Reisert, I, 1995
)
0.29
" KA and AMPA were found to be more toxic than either N-methyl-D-aspartate (NMDA), quinolinate, or glutamate, both under normal conditions and under states of energy deprivation."( Kainate toxicity in energy-compromised rat hippocampal slices: differences between oxygen and glucose deprivation.
Rigor, BM; Schurr, A, 1993
)
0.29
" In addition, Tat, at similar concentrations, was toxic to human fetal neurons in culture."( Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity.
Brownstone, RM; Geiger, JD; Knudsen, BE; Magnuson, DS; Nath, A, 1995
)
0.29
"The toxic effects of ethanol on rat cortical cell cultures were compared with neuronal damage induced by glucose deprivation."( Ethanol and glucose-deprivation neurotoxicity in cortical cell cultures.
Ehmann, S; Singh, SP; Snyder, AK, 1994
)
0.29
"5-5 mg/kg, CGP 37849 potentiated the adverse effects but not the anticonvulsant activity of 50 mg/kg valproate."( Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats.
Hönack, D; Löscher, W, 1993
)
0.29
"Extracellular levels of endogenous glutamate are relatively high in the developing rabbit retina but nonetheless appear to promote cell survival and developmental processes at concentrations considered toxic in the adult."( N-methyl-D-aspartate-mediated glutamate toxicity in the developing rabbit retina.
Haberecht, MF; Lo, GJ; Mitchell, CK; Redburn, DA, 1997
)
0.3
" Activation of the coagulation system and adverse effects of homocysteine on the endothelium and vessel wall are believed to underlie disease pathogenesis."( Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor.
Arnelle, DR; Choi, YB; D'Emilia, DM; Kim, WK; Kumar, S; Lipton, SA; Rayudu, PV; Stamler, JS, 1997
)
0.3
" We conclude that exposures to toxic levels of NO cause prolonged disruption of [Ca2+]i homeostatic mechanisms, and that the resulting persistent [Ca2+]i elevations contribute to the delayed neurotoxicity of NO."( Disrupted [Ca2+]i homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons.
Brorson, JR; Zhang, H, 1997
)
0.3
" Putrescine was moderately toxic but only at 500 microM concentration."( Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells.
Ciani, E; Contestabile, A; Dall'Olio, R; Gandolfi, O; Sparapani, M, 1997
)
0.3
"In this study, the anticonvulsant and adverse effects of compounds that belong to four different categories of systemically available N-methyl-D-aspartate (NMDA) receptor ligands were compared, namely the competitive antagonist CGP 40116, the noncompetitive antagonist MK-801 (dizocilpine), the glycineB receptor antagonist L-701,324, and the glycineB receptor high-efficacy partial agonist D-cycloserine."( Anti-convulsant and adverse effects of the glycineB receptor ligands, D-cycloserine and L-701,324: comparison with competitive and non-competitive N-methyl-D-aspartate receptor antagonists.
Wlaź, P, 1998
)
0.3
"Extracellular glutamate is kept below a toxic level by glial and neuronal glutamate transporters."( Gliotoxicity in hippocampal cultures is induced by transportable, but not by nontransportable, glutamate uptake inhibitors.
Cohen-Solal, C; de Jesus Ferreira, MC; Guiramand, J; Martin, A; Récasens, M; Vignes, M, 2005
)
0.33
" Hippocampi aged in vitro were significantly more sensitive to the toxic effects of multiple cycles of CIE than were non-aged hippocampi."( Ethanol withdrawal is required to produce persisting N-methyl-D-aspartate receptor-dependent hippocampal cytotoxicity during chronic intermittent ethanol exposure.
Berry, JN; Prendergast, MA; Reynolds, AR; Sharrett-Field, L, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" When eliprodil was combined with an ineffective dose of L-701,324 (2."( Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats.
Ebert, U; Löscher, W; Wlaź, P, 1999
)
0.3

Dosage Studied

The dose-response relationship of quisqualate acting at the N-methyl-D-aspartate (NMDA) receptor was measured. The NMDA receptor antagonists D(-)-2-amino-5-phosphonovalerate (D-AP5), phencyclidine and Mg2+ shifted the NMDA dose- response curve to the right.

ExcerptRelevanceReference
" In the majority of neurons two phases in the dose-response relationship could be distinguished."( Membrane currents induced by L-homocysteic acid in mouse cultured hippocampal neurons.
Vlachová, V; Vyklický, L, 1992
)
0.28
" L-Aspartate (L-Asp) produced a similar dose-response relationship."( Electrogenic uptake contributes a major component of the depolarizing action of L-glutamate in rat hippocampal slices.
Blake, JF; Brown, MW; Collingridge, GL; Frenguelli, BG, 1991
)
0.28
" This is observed as a shift to the right in the NMDA dose-response curves for both the positive and negative postsynaptic components of the evoked tectal response."( Chronic application of NMDA decreases the NMDA sensitivity of the evoked tectal potential in the frog.
Cline, HT; Constantine-Paton, M; Debski, EA; McDonald, JW, 1991
)
0.28
" In the presence of 10 microM KA, the dose-response curve of QU became biphasic, whereas with 50 microM KA, a reduction of the response was seen around 1-100 microM QU."( Interactions of glutamate receptor agonists coupled to changes in intracellular Ca2+ in rat cerebellar granule cells in primary culture.
Akerman, KE; Holopainen, I; Louve, M, 1991
)
0.28
" Activity-dependent plasticity was also blocked if spontaneous activity was suppressed with dilute tetrodotoxin (TTX; 5-10 nM), a dosage that reduces excitability of neurons but is insufficient to block sodium-dependent action potentials."( Calcium, network activity, and the role of NMDA channels in synaptic plasticity in vitro.
Fields, RD; Nelson, PG; Yu, C, 1991
)
0.28
" A half-maximum dose of 55 microM was calculated from the sigmoid NMDA dose-response curve in the presence of 10 microM Gly."( Proteolytic enzymes do not destroy the N-methyl-D-aspartate (NMDA) sensitivity of acutely isolated hippocampal CA1 and CA3 neurons from postnatal rats.
Gündel, J; Matthies, H; Steinhäuser, C, 1990
)
0.28
" Analyses of dose-response curves of these inward currents indicate that both the QA and KA currents were competitively blocked by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), while the NMDA current was blocked non-competitively."( Glutamate receptor agonist-induced inward currents in spinal dorsal horn neurons dissociated from the adult rats.
Arancio, O; MacDermott, AB; Murase, K; Yoshimura, M, 1991
)
0.28
" The dose-response relationship of quisqualate acting at the N-methyl-D-aspartate (NMDA) receptor was measured as that portion of the whole-cell current activated by quisqualate that could be blocked by the addition of two NMDA antagonists, 5-fluoroindole-2-carboxylic acid, a competitive antagonist of the NMDA receptor-associated glycine site, and D-2-amino-5-phosphonovalerate, a competitive NMDA binding site antagonist."( Quisqualate activates N-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture.
Grudt, TJ; Jahr, CE, 1990
)
0.45
" The effect of D,L-2-amino-5-phosphonovalerate (APV) on the dose-response relationship was also studied."( The dose-response relationship for N-methyl-D-aspartate currents in cultured rat septal neurons: effects of magnesium ions and 2-amino-5-phosphonovaleric acid.
Ebina, Y; Harada, K; Nagaoka, S; Shingai, R, 1990
)
0.61
" Apomorphine-induced cage climbing behavior was partially decreased by lower dosages of GDEE, but was almost completely blocked by the highest dosage tested."( A possible role of AA2 excitatory amino acid receptors in the expression of stimulant drug effects.
Cannon-Spoor, HE; Freed, WJ, 1990
)
0.28
" Although the dose-response curve is hyperbolic with an ED50 of 78 microM, glutamate apparently activates 2 types of receptors on motoneurons."( Characterization of excitatory amino acid receptors expressed by embryonic chick motoneurons in vitro.
Fischbach, GD; O'Brien, RJ, 1986
)
0.27
" The NMDA receptor antagonists D(-)-2-amino-5-phosphonovalerate (D-AP5), phencyclidine and Mg2+ shifted the NMDA dose-response curve to the right in a parallel manner."( A grease-gap method for studying the excitatory amino acid pharmacology of CA1 hippocampal pyramidal cells.
Bowe, MA; Martin, D; Nadler, JV, 1989
)
0.55
" APH caused motor incoordination at a dosage of 125 mg/kg, and a prolonged motor impairment was present after administration of APH, 250 mg/kg."( Impaired motor coordination in mice induced by 2-amino-7-phosphonoheptanoic acid (APH), glutamic acid diethyl ester (GDEE), and other compounds.
Freed, WJ, 1989
)
0.28
" Analysis of iontophoretic dose-response curves indicated that DL-APV was a competitive antagonist."( Action of excitatory amino acids and their antagonists on hippocampal neurons.
Hablitz, JJ, 1985
)
0.27
" When applied in combination with fixed concentrations of cis-PDA, NMDA evoked concentration-dependent depolarizations superimposed upon the basal cis-PDA-evoked depolarizations, the dose-response curve for which intercepted the control dose-response curve and was subsequently moved to the right compared with the control curve."( Quantitative studies of N-methyl-D-aspartate, 2-amino-5-phosphonovalerate and cis-2,3-piperidine dicarboxylate interactions on the neonatal rat spinal cord in vitro.
Collins, KJ; Wheatley, PL, 1986
)
0.53
" A dose-response relation for NMDA activation indicated that bath application of 1 and 5 microM NMDA had little or no effect on the response to a paired stimulus pulse (triggered response) and did not induce spontaneous bursting."( The NMDA receptor antagonist 2-amino-5-phosphonovalerate blocks stimulus train-induced epileptogenesis but not epileptiform bursting in the rat hippocampal slice.
Anderson, WW; Swartzwelder, HS; Wilson, WA, 1987
)
0.56
" Pharmacologically specific results were obtained rapidly and reliably, using a cumulative dosing procedure."( A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats.
Koek, W; Ornstein, P; Woods, JH, 1987
)
0.48
" We found that excitatory amino acid agonists evoked somatostatin release in the following order of potency: quisqualate greater than glutamate = N-methyl-D-aspartate (NMDA) greater than kainate, as calculated from the dose-response curves."( Glutamate stimulates somatostatin release from diencephalic neurons in primary culture.
Astier, H; Tapia-Arancibia, L, 1988
)
0.27
" The dose-response relationship of EAA (N-methyl-D-aspartate (NMDA), kainate, quisqualate and glutamate)-induced activation revealed qualitative and quantitative differences in their pattern of action, suggesting that these agonists act at distinct receptors."( Behavioral classification of excitatory amino acid receptors in mouse spinal cord.
Raigorodsky, G; Urca, G, 1988
)
0.27
" Dose-response studies demonstrated that the synaptic input to NTS units was substantially blocked by 2-amino-5-phosphonovaleric acid (APV) at perfusion concentrations of 1 mM, by kynurenic acid (KYN) at 10 mM, and glutamate diethylester (GDEE) at 10 mM."( Excitatory amino acid receptors intrinsic to synaptic transmission in nucleus tractus solitarii.
Felder, RB; Miller, BD, 1988
)
0.27
" Dose-response relationships showed a close association between seizure activity (measured by EEG) and extracellular Ca2+ changes in the injected area."( Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca2+ decrease assessed in the hippocampus by brain dialysis.
Angelico, P; Samanin, R; Stasi, MA; Vezzani, A; Wu, HQ, 1988
)
0.27
" To determine if acidic amino acid pathways were involved in this elevation, a low dosage of a selective NMDA antagonist, 2-amino-7-phosphonoheptanoic acid (APH) was injected intracerebroventricularly 4 min before having rats swim 4 laps."( 2-Amino-7-phosphonoheptanoic acid, a selective N-methyl-D-aspartate antagonist, blocks swim-induced elevation of cerebellar cyclic guanosine monophosphate.
McCaslin, PP; Morgan, WW, 1986
)
0.27
" Dose-response curves showed that DCG-IV was weaker than NMDA but more potent than glutamate in eliciting agonist-gated currents."( Metabotropic glutamate receptor agonist DCG-IV as NMDA receptor agonist in immature rat hippocampal neurons.
Opitz, T; Pidoplichko, VI; Reymann, KG; Shinozaki, H; Wilsch, VW, 1994
)
0.29
") caused vacuolation in cortical pyramidal neurons in the posterior cingulate cortex four hours after dosing and this dose of CGP 37849 caused a pattern of limbic glucose metabolism activation similar to that seen after dizocilpine."( Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism.
Hargreaves, RJ; Hill, RG; Iversen, LL; Rigby, M; Smith, D, 1993
)
0.29
" The actions of the hepoxilins showed a sharp dose-response relationship, with minimal threshold or no effect at 3 nM (n = 21) and maximal effects at 10 nM (n = 33)."( Formation and electrophysiological actions of the arachidonic acid metabolites, hepoxilins, at nanomolar concentrations in rat hippocampal slices.
Carlen, PL; Gurevich, N; Pace-Asciak, CR; Reynaud, D; Wu, PH; Zhang, L, 1994
)
0.29
" The excitatory effect showed a dose-response relationship."( [Effects of L-glutamic acid and its antagonist on spontaneous discharge of nucleus paragigantocellularis lateralis neurons in brainstem slice in rat].
Liu, H; Xu, M, 1994
)
0.29
" The dose-response curve appears in diphase, and the largest magnitude of LTP has been obtained at the GM1 concentration of 50 mg/L in incubation ACSF."( The role of monosialoganglioside GM1 in LTP-induction in rat hippocampal slices.
Li, YX; Mei, ZT, 1994
)
0.29
" Dose-response curves were evaluated by means of an ethological method in which behavioral sequences typical of S and R animals were quantitated."( NMDA-dependent audiogenic seizures are differentially regulated by inferior colliculus subnuclei.
Garcia-Cairasco, N; Terra, VC, 1994
)
0.29
" In addition, neuronal death induced by brief NMDA exposure in both mixed neuronal-glial and pure neuronal cultures was increased by TGFbeta2 (1-30 ng/ml) with a similar dose-response curve."( Transforming growth factor-beta2 increases NMDA receptor-mediated excitotoxicity in rat cerebral cortical neurons independently of glia.
Brown, GJ; Kane, CJ; Phelan, KD, 1996
)
0.29
"5 mg/kg, respectively, in a bell-shaped dose-response relationship."( Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.
Danysz, W; Frankiewicz, T; Parsons, CG; Zajaczkowski, W, 1997
)
0.3
" mexiletine, an orally active congener of lidocaine, on strychnine allodynia and compared the dose-response relationship of mexiletine in normal (noxious paw pinch) versus abnormal (i."( Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat.
Hodge, E; Khandwala, H; Loomis, CW, 1997
)
0.3
" Evoked inhibitory postsynaptic currents (IPSCs) were decreased by kainate by up to 90%, showing a bell-shaped dose-response curve similar to that of native kainate-selective receptors."( Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus.
Herreras, O; Lerma, J; Rodríguez-Moreno, A, 1997
)
0.3
" 1, spontaneous motor activity (locomotor activity and rearing) was measured in an open-field after bilateral AP5 injection into the hippocampus, and it was shown that AP5 did not affect general activities within the dosage used in the present study."( Effects of intrahippocampal AP5 treatment on radial-arm maze performance in rats.
Ichitani, Y; Iwasaki, T; Kawabe, K, 1998
)
0.3
" The NMDA receptor antagonist D-AP5 reversed this effect, leaving the (1S,3R)-ACPD dose-response curve unchanged in naive animals."( mGluR activation reveals a tonic NMDA component in inflammatory hyperalgesia.
Berthele, A; Boxall, SJ; Tölle, TR; Urban, L; Zieglgänsberger, W, 1998
)
0.3
" Since the GLU receptors present at NMJ have been reported to be predominantly N-methyl-D-aspartate (NMDA) subtype, some non-competitive and competitive NMDA receptor blockers, MK801, ketamine, dextromethorphan and CGP 37849, and GLU release inhibitors, clonidine, guanfacine, tizanidine were used at their optimum concentrations in medium after having found them from dose-response curves."( N-methyl-D-aspartate antagonists, glutamate release inhibitors, 4-aminopyridine at neuromuscular transmission.
Günel, MA; Kara, I; Koyuncuoğlu, H; Nurten, A; Yamantürk, P, 1998
)
0.3
"Chronic dosing with the glycine partial NMDA agonist, 1-aminocyclopropanecarboxylic acid (ACPC) elicited an altered allosteric regulation of cortical NMDA receptor binding."( Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.
Boje, KM; Lakhman, SS, 1998
)
0.3
" Generalized tonic-clonic seizures were at first modified--their tonic phase was restricted to forelimbs, then selectively suppressed--and with increasing dosage the clonic phase was blocked too."( Anticonvulsant action of a NMDA receptor antagonist CGP 40116 varies only quantitatively during ontogeny in rats.
Haugvicová, R; Mares, P, 1998
)
0.3
" Time course and dose-response experiments with MSO showed significant [3H]glutamate release, which was partially attenuated by AP5."( Methionine sulfoximine shows excitotoxic actions in rat cortical slices.
Bains, JS; Curry, K; Pasqualotto, BA; Shaw, CA, 1999
)
0.3
" The excitatory effects of L-Glu and BIC and the inhibitory effects of GABA showed a dose-response relationship."( [Effects of L-glutamic acid, gamma-aminobutyric acid and their respective antagonists on spontaneous discharge of nucleus paragigantocellularis lateralis neurons in rats].
Li, L; Xu, M; Zheng, Y, 1997
)
0.3
" After obtaining dose-response curves for each agent, combinations of morphine and AP-5, ACEA 1021 or ACEA 2752 were tested for their effect on the number of flinches in the formalin test and for associated side-effects, such as motor disturbances, flaccidity, and agitation/allodynia."( Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test.
Nishiyama, T, 2000
)
0.31
" Following the dose-response curve, a dose of 3 nmol of NMDA was selected."( Nitric oxide mediates depressor responses by activation of N-methyl-D-aspartate receptors in the nucleus tractus solitarius of cat.
Chai, CY; Wu, WC; Yang, CY, 2000
)
0.31
" The noncompetitive antagonist MK-801 and a glycine-site blocker were equally neuroprotective in both normal and reduced conditions, but there was a significant rightward shift in the dose-response curves of the competitive antagonists APV and CPP and the uncompetitive antagonist memantine."( Reducing conditions significantly attenuate the neuroprotective efficacy of competitive, but not other NMDA receptor antagonists in vitro.
Eshak, M; Iannotti, F; Pringle, AK; Self, J, 2000
)
0.31
" Dose-response studies in young male adult Sprague-Dawley rats and Swiss mice, after the postacquisition intracerebroventricular injection of steroid, showed an U-inverted curve for memory performance and indicated a greater responsiveness in rats compared with mice."( The synthetic enantiomer of pregnenolone sulfate is very active on memory in rats and mice, even more so than its physiological neurosteroid counterpart: distinct mechanisms?
Akwa, Y; Baulieu, EE; Covey, DF; Ladurelle, N, 2001
)
0.31
" At early time points, NMDA receptor and NGC activation enhance descending facilitation; as time progresses, the dose-response curve of NMDA shifts to the left and descending inhibition dominates and masks any descending facilitation."( The roles of NMDA receptor activation and nucleus reticularis gigantocellularis in the time-dependent changes in descending inhibition after inflammation.
Dubner, R; Ren, K; Terayama, R, 2002
)
0.31
"Systemic or regional administration of the non-competitive NMDA antagonist dizocilpine into the VTA significantly increased the rate of heroin SA and shifted the heroin dose-response curve to the right."( Blockade of ionotropic glutamatergic transmission in the ventral tegmental area reduces heroin reinforcement in rat.
Stein, EA; Xi, ZX, 2002
)
0.31
" In contrast, in human neocortical preparations obtained from epilepsy surgery, in approximately 20% of the slices spontaneous epileptiform activity appeared with this bicuculline dosage without SDs."( Differential sensitivity to induction of spreading depression by partial disinhibition in chronically epileptic human and rat as compared to native rat neocortical tissue.
Hagemann, G; Koch, UR; Köhling, R; Redecker, C; Speckmann, EJ; Straub, H, 2003
)
0.32
"3 microM, respectively; whereas the dose-response curve of D,L-homocysteine revealed an IC50 of 401 microM."( Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity.
Fleischer, W; Görtz, P; Hoinkes, A; Otto, F; Schwahn, B; Siebler, M; Wendel, U, 2004
)
0.32
" Using a set of experiments aimed at manipulate a putative l-glutamate/NMDA/NO signal transduction pathway, we have demonstrated, by quantitative real-time PCR, that NMDA enhances the expression of GnRH mRNA in a dose-response manner."( Control of GnRH expression in the olfactory lobe of Octopus vulgaris.
De Lisa, E; Di Cosmo, A; Di Cristo, C, 2009
)
0.35
" In pretrained rats, the dose-response function was shifted such that, in watermaze 2, spatial learning was normal at this low concentration, with a deficit at higher infusion concentrations."( Upstairs/downstairs revisited: spatial pretraining-induced rescue of normal spatial learning during selective blockade of hippocampal N-methyl-d-aspartate receptors.
Inglis, J; Martin, SJ; Morris, RG, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.16230.003245.467312,589.2998AID2517
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency4.46680.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency15.101423.934123.934123.9341AID1967
D(1A) dopamine receptorHomo sapiens (human)Potency1.63590.02245.944922.3872AID488982
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Ki100.00000.00000.41052.7800AID92947
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.600310.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.56000.00030.86666.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Ki100.00000.00380.79754.1000AID91469
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.630610.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.56000.00030.68056.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.29000.00061.525710.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.56000.00030.70716.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.747210.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.56000.00030.81966.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.741110.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.56000.00030.70726.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.741110.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.56000.00030.70726.6900AID143145; AID143314; AID145325
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.741110.0000AID143312; AID144603; AID144763; AID144905
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.56000.00030.70726.6900AID143145; AID143314; AID145325
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID376759Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 0.1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID144456Displacement of [3H]CPP from N-methyl-D-aspartate glutamate receptor in rat brain membrane1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists.
AID376760Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID195983Percentage response to 0.5 mM of L-Glutamic acid at 1 mM in rat striatum slices.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Bicyclic lactones derived from kainic acid as novel selective antagonists of neuroexcitatory amino acids.
AID42542sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 before exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID42541sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 after reversal with L-alpha-AA1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID196560In vitro antagonist activity by its ability to inhibit glutamate-induced accumulation of [45Ca2+]- in cultured rat cortical neurons.1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced alpha-amino acids as competitive N-methyl-D-aspartic acid antagonists.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID91469Binding affinity towards Ionotropic glutamate receptor kainate using [3H]-kainic acid as radioligand; Inactive1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID145325Displacement of [3H]CPP or [3H]-CGS- 19755 from rat N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Modeling of competitive phosphono amino acid NMDA receptor antagonists.
AID92041Percent control measured by evaluating the inhibition of 3 nM [125I]PhTX-343-lysine binding to glutamate receptors in rat cortical membranes1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes.
AID92947Binding affinity towards AMPA receptor using [3H]AMPA as radioligand; Inactive1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID361436Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 10 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry2002Journal of natural products, Nov, Volume: 65, Issue:11
Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots.
AID195847Percentage response to 0.1 mM of kainic acid (KA) at 1 mM in rat striatum slices.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Bicyclic lactones derived from kainic acid as novel selective antagonists of neuroexcitatory amino acids.
AID143312Compound was tested in vitro for its inhibitory activity against N-methyl-D-aspartate glutamate receptor using [3H]MK-8011991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID180480Percent inhibition of glutamate activity against cGMP was determined1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID139976Tested for antagonistic activity against electrophysiological responses induced by NMDA (10 uM) in culture mouse cortical neurons at 10 uM1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Preferred antagonist binding state of the NMDA receptor: synthesis, pharmacology, and computer modeling of (phosphonomethyl)phenylalanine derivatives.
AID195987Percentage response to 30 uM of N-methyl-D-aspartic acid (NMDA) at 1 mM in rat striatum slices.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Bicyclic lactones derived from kainic acid as novel selective antagonists of neuroexcitatory amino acids.
AID195980Percentage response to 0.1 mM of quisqualic acid at 1 mM in rat striatum slices.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Bicyclic lactones derived from kainic acid as novel selective antagonists of neuroexcitatory amino acids.
AID143145Compound was evaluated for its ability to displace [3H]CPP ligand from N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Modeling of competitive phosphono amino acid NMDA receptor antagonists.
AID144603Binding affinity was determined by the ability to displace [3H]-CPP from N-methyl-D-aspartate glutamate receptor of rat brain1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity relationships and pharmacological evaluation.
AID144334Binding affinity for glutamate-stimulated TCP binding site of N-methyl-D-aspartate glutamate receptor from rat brain by using [3H]-TCP as radioligand; ant = antagonist1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity relationships and pharmacological evaluation.
AID144905Inhibitory activity evaluated by its ability to displace [3H]CPP from N-methyl-D-aspartate glutamate receptor in rat cortical membranes at 10E-5 concentration of the compound1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced alpha-amino acids as competitive N-methyl-D-aspartic acid antagonists.
AID361434Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 0.1 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry2002Journal of natural products, Nov, Volume: 65, Issue:11
Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots.
AID147420Compound was tested in vitro for Non N-methyl-D-aspartate glutamate receptor binding using [3H]- -Kainate1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID143309In vitro binding affinity towards N-methyl-D-aspartate glutamate receptor of the glutamate receptor using [3H]CPP as radioligand in rat cerebral cortical membranes.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID361435Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 1 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry2002Journal of natural products, Nov, Volume: 65, Issue:11
Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots.
AID376761Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 10 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID42543sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4,L-AP5 and L-AP6 after exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID144763In vitro binding affinity for rat cortical membrane N-methyl-D-aspartate glutamate receptor determined using [3H]CPP as radioligand2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID143314Compound was tested in vitro for N-methyl-D-aspartate glutamate receptor binding using [3H]L-glutamate1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID74396Concentration required to inhibit glucosamine-6-phosphate synthase (GFAT) isolated from Candida albicans2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Multisubstrate analogue inhibitors of glucosamine-6-phosphate synthase from Candida albicans.
AID139977Tested for antagonistic activity against electrophysiological responses induced by NMDA (10 uM) in culture mouse cortical neurons at 100 uM1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Preferred antagonist binding state of the NMDA receptor: synthesis, pharmacology, and computer modeling of (phosphonomethyl)phenylalanine derivatives.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,274)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990430 (10.06)18.7374
1990's1956 (45.77)18.2507
2000's1255 (29.36)29.6817
2010's617 (14.44)24.3611
2020's16 (0.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.31 (24.57)
Research Supply Index8.39 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.02%)5.53%
Reviews21 (0.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4,371 (99.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]